{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:26:08Z","timestamp":1791973568129,"version":"4.4.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Daiichi Sankyo, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Pexidartinib is approved in the US, Taiwan, and Korea for adults with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery based on the phase III ENLIVEN study (NCT02371369). We report the final long-term efficacy and safety results from ENLIVEN.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Adults with symptomatic TGCT not eligible for surgery were enrolled and randomized to pexidartinib or placebo (part 1). The blinded phase (part 1) ended at week 25; patients received pexidartinib (800\u00a0mg\/day) until progression, toxicity, or study completion (part 2). This analysis includes patients who received pexidartinib at any time during ENLIVEN. Centrally reviewed overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and tumor volume score (TVS), time to response, duration of response (DOR), patient-reported outcomes (PROs), and long-term safety were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 91 patients received pexidartinib. With a median follow-up of 31.2 (range: 2-66) months, ORR was 60.4% and 68.1% by RECIST and TVS, respectively. Median DOR by RECIST was not reached (range: 0.03-63.4 months). Most responses were within the first 6 months of treatment; most responders were on 800\u00a0mg vs 600\/400\u00a0mg dose levels, respectively. Throughout parts 1 and 2, 3 (3%) patients had progressive disease per RECIST without dose reduction\/interruption. PROs improved or were maintained. The most common grade 3\/4 treatment-emergent adverse events were aspartate aminotransferase (AST) increase (9%), alanine aminotransferase (ALT) increase (10%), and hypertension (8%). Twenty-eight (31%) patients had AST or ALT \u22653 times the upper limit of normal (ULN); 17 (19%) patients had AST or ALT \u22655 times the ULN. No new safety signals were observed after long-term pexidartinib treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Final long-term ENLIVEN results demonstrated that pexidartinib sustained clinical benefit, with increased ORR by RECIST and TVS compared to the end of the blinded phase at week 25. No new safety signals were reported.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae345","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T13:03:13Z","timestamp":1751634193000},"source":"Crossref","is-referenced-by-count":14,"title":["Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4384-9448","authenticated-orcid":false,"given":"Andrew J","family":"Wagner","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute, Harvard Medical School, Boston , MA 02215 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D","family":"Tap","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College , New York, NY 10065 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5949-8120","authenticated-orcid":false,"given":"Sebastian","family":"Bauer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Hospital Essen , Essen 45147 ,","place":["Germany"]},{"name":"Department of Translational Oncology, University of Duisburg-Essen , Essen 47057 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-120X","authenticated-orcid":false,"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[{"name":"Centre L\u00e9on B\u00e9rard and Universit\u00e9 Claude Bernard , Lyon 69100 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayesh","family":"Desai","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre , Melbourne, VIC 3000 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center , Leiden 2333 ,","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Palmerini","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Ortopedico Rizzoli , Bologna 40136 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher W","family":"Ryan","sequence":"additional","affiliation":[{"name":"School of Medicine, Oregon Health & Science University , Portland, OR 97239 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Peterfy","sequence":"additional","affiliation":[{"name":"Spire Sciences , Boca Raton, FL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0802-1186","authenticated-orcid":false,"given":"John H","family":"Healey","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College , New York, NY 10065 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-7656","authenticated-orcid":false,"given":"Michiel","family":"van de Sande","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center , Leiden 2333 ,","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Qian","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc. , Basking Ridge, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale E","family":"Shuster","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc. , Basking Ridge, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Rajper","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc. , Basking Ridge, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5929-3798","authenticated-orcid":false,"given":"Xin","family":"Ye","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc. , Basking Ridge, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Tecson","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc. , Basking Ridge, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret J","family":"Wooddell","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc. , Basking Ridge, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Stacchiotti","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori , Milan 20133 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"2025070409030802600_CIT0001","first-page":"102","volume-title":"Tenosynovial Giant Cell Tumour, Diffuse Type. World Health Organization Classification of Tumours of Soft Tissue and Bone","author":"de Saint Aubain Somerhausen","year":"2013","edition":"4th ed"},{"key":"2025070409030802600_CIT0002","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejca.2016.04.022","article-title":"Diffuse-type tenosynovial giant cell tumour: current treatment concepts and future","volume":"63","author":"Staals","year":"2016","journal-title":"Eur J Cancer"},{"key":"2025070409030802600_CIT0003","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.2196\/ijmr.9325","article-title":"The patient perspective on the impact of tenosynovial giant cell tumors on daily living: crowdsourcing study on physical function and quality of life","volume":"7","author":"Mastboom","year":"2018","journal-title":"Interact J Med Res"},{"key":"2025070409030802600_CIT0004","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.3899\/jrheum.160816","article-title":"Tenosynovial giant cell tumor: incidence, prevalence, patient characteristics, and recurrence. A registry-based cohort study in Denmark","volume":"44","author":"Ehrenstein","year":"2017","journal-title":"J Rheumatol"},{"key":"2025070409030802600_CIT0005","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1080\/17453674.2017.1361126","article-title":"Higher incidence rates than previously known in tenosynovial giant cell tumors","volume":"88","author":"Mastboom","year":"2017","journal-title":"Acta Orthop"},{"key":"2025070409030802600_CIT0006","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13023-021-01820-6","article-title":"The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study","volume":"16","author":"Bernthal","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"2025070409030802600_CIT0007","doi-asserted-by":"publisher","first-page":"11560","DOI":"10.1200\/jco.2018.36.15_suppl.11560","article-title":"First prospective observational study in diffuse-type tenosynovial giant cell tumors","volume":"36","author":"Mastboom","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025070409030802600_CIT0008","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1411366","article-title":"Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor","volume":"373","author":"Tap","year":"2015","journal-title":"N Engl J Med"},{"key":"2025070409030802600_CIT0009","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"key":"2025070409030802600_CIT0010","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/cncr.33312","article-title":"Long-term outcomes of pexidartinib in tenosynovial giant cell tumors","volume":"127","author":"Gelderblom","year":"2021","journal-title":"Cancer"},{"key":"2025070409030802600_CIT0011","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jclinepi.2013.10.024","article-title":"The PROMIS Physical Function item bank was calibrated to a standardized metric and shown to improve measurement efficiency","volume":"67","author":"Rose","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"2025070409030802600_CIT0012","author":"HealthMeasures","year":"2022"},{"key":"2025070409030802600_CIT0013","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1158\/1078-0432.CCR-22-1898","article-title":"Interactions in CSF1-driven tenosynovial giant cell tumors","volume":"28","author":"van IJzendoorn","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025070409030802600_CIT0014","volume-title":"TURALIO\u00ae (Pexidartinib) Capsules, for Oral Use [package insert]","year":"2020"},{"key":"2025070409030802600_CIT0015","volume-title":"TURALIO\u00ae (Pexidartinib) Capsules, for Oral Use [package insert]","year":"2023"},{"key":"2025070409030802600_CIT0016","doi-asserted-by":"publisher","first-page":"e863","DOI":"10.1002\/onco.13629","article-title":"Pexidartinib long-term hepatic safety profile in patients with tenosynovial giant cell tumors","volume":"26","author":"Lewis","year":"2021","journal-title":"Oncologist"},{"key":"2025070409030802600_CIT0017","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"2025070409030802600_CIT0018","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1007\/s12032-012-0204-1","article-title":"Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors","volume":"29","author":"Adenis","year":"2012","journal-title":"Med Oncol"},{"key":"2025070409030802600_CIT0019","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.2217\/fon-2021-1437","article-title":"CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden","volume":"18","author":"Peterfy","year":"2022","journal-title":"Future Oncol"},{"key":"2025070409030802600_CIT0020","doi-asserted-by":"publisher","first-page":"7402570","DOI":"10.1155\/2017\/7402570","article-title":"Limb amputation after multiple treatments of tenosynovial giant cell tumour: series of 4 Dutch cases","volume":"2017","author":"Mastboom","year":"2017","journal-title":"Case Rep Orthop"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyae345\/63669877\/oyae345.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyae345\/63669877\/oyae345.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T13:03:15Z","timestamp":1751634195000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae345\/8186020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae345","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,7]]},"article-number":"oyae345"}}